Iovance Biotherapeutics (IOVA) EBIT Margin (2019 - 2026)
Iovance Biotherapeutics' EBIT Margin was -52.26% in Q2 2026, up 137.51 percentage points from -189.78% a year earlier and up 61.19 percentage points from the prior quarter.
Iovance Biotherapeutics (IOVA) EBIT Margin (2019 - 2026) Analysis & Trends
On a trailing twelve-month basis, Iovance Biotherapeutics' EBIT Margin was -92.72% through Jun 30, 2026, up 77.30 percentage points year-over-year; for FY2025, it came in at -153.08%, up 87.85 percentage points from FY2024.
- In earlier years, EBIT Margin was -240.92% in FY2024 (+38494.07 pp) and -38734.99% in FY2023.
- The Q2 2026 figure marks the highest quarterly EBIT Margin in data going back to Q2 2023.
- Compared with a year earlier, EBIT Margin has increased for nine straight quarters, with an average year-over-year change of +8349.36 percentage points over the last eight quarters.
- Over the past five years, the year-over-year gain in EBIT Margin ranged from 11.42 percentage points (Q3 2025) to 45926.99 percentage points (Q2 2024).
- Per Business Quant data, IOVA's EBIT Margin in the three quarters before Q2 2026 was -113.46% (Q1 2026), -84.66% (Q4 2025) and -140.69% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Iovance Biotherapeutics | 3.74 Bn | 2.45 Bn | 73.44 Mn | -19.73% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -19.73% |
| Jun 30, 2026 | -52.26% |
| Mar 31, 2026 | -113.46% |
| Dec 31, 2025 | -84.66% |
| Sep 30, 2025 | -140.69% |
| Jun 30, 2025 | -189.78% |
| Mar 31, 2025 | -245.76% |
| Dec 31, 2024 | -117.48% |
| Sep 30, 2024 | -152.11% |
| Jun 30, 2024 | -327.63% |
| Mar 31, 2024 | -16,464.62% |
| Dec 31, 2023 | -25,156.85% |
| Sep 30, 2023 | -25,236.89% |
| Jun 30, 2023 | -46,254.62% |
| Mar 31, 2023 | -3,180.03% |
| Dec 31, 2022 | -6,233.90% |
| Sep 30, 2022 | -12,920.85% |
| Jun 30, 2022 | -25,904.94% |
| Mar 31, 2022 | -86,521.70% |
| Dec 31, 2021 | -73,677.78% |
Iovance Biotherapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "IOVA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=IOVA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();